Following Nutraceutix Acquisition, Probi Launches New Line of Probiotic Strains for Digestive and Immune Support
Probi Select is a patented and clinically documented line of probiotic strains curated to help provide gastrointestinal and immune support.
Photo © iStockphoto.com/Raycat
After acquiring Nutraceutix in October of 2016, Probi is rolling out a range of curated probiotic strains for gastrointestinal and immune support. Probi (Lund, Sweden), now a full-scale manufacturing company, is best known as the maker of LP299V, which, according to the company, is the world’s most researched strain of Lactobacillus plantarum. The company is now rolling out the following probiotic strains as part of the Probi brand: Probi Rhamnosus 6594 (Lactobacillus rhamnosus 6594), Probi Paracasei 13434 (Lactobacillus paracasei 13434), and Probi Plantarum 6595 (Lactobacillus plantarum 6595).
Both Probi Rhamnosus 6594 and Probi Paracasei 13434 ingredients are touted as beneficial to general health and supportive for immune defense. Probi Rhamnosus 6594 is specifically formulated for infants, while Probi Paracasei 13434 is intended for the general population. Probi Plantarum 6595 supports gastrointestinal and immune health and is said to reduce the risk of infection and inflammation, reduce gut permeability, and support immune defense in sensitive groups, such as athletes and the elderly.
Probi says it expects that the wider range of ingredients in the new line will make finding clinically documented strains even easier for companies in the probiotic market. According to Niklas Bjärum, president, Probi USA and Global Sales & Marketing, Probi Group: “It is extremely exciting to launch the new probiotic line-Probi Select. Through the integration of Nutraceutix, Probi has established a complete probiotic offering with the Probi Premium, Probi Select, and Probi LiveBac ranges. Probi is now a true ‘One stop shop’ for any consumer goods company wanting to drive their position in the probiotic market.”
The strains in Probi Select are clinically proven to survive to survive the passage through the gastrointestinal tract, according to the company, and thus benefit gut microbiota. Microbiota are essential to digestion, absorption of nutrients, and helping to balance the immune system, and helps protect against pathogens.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.
